Drugs / letibotulinumtoxinA
letibotulinumtoxinA
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 34 trials | ||||||
| Phase 3 | NCT03985982 | Apr → Dec 2019 | — | Croma-Pharma GmbH | Completed | No outcome recorded |
| Phase 3 | NCT05380154 | May 2017 → Jan 2018 | — | Hugel | Completed | No outcome recorded |
| Phase 3 | NCT02677805 | Mar → Sep 2016 | — | Croma-Pharma GmbH | Completed | No outcome recorded |
| Phase 3 | NCT02677298 | Mar → Nov 2016 | — | Croma-Pharma GmbH | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07668375 | Jan → Apr 2026 | temporomandibular joint dysfunction syndrome | PAEC General Hospital, Islamabad | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT03408236 Comparator | Jan → Dec 2018 | — | Hugel | Completed | No outcome recorded |
| Phase 3 | NCT01791920 Comparator | Aug → Dec 2011 | skin atrophy | Hugel | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07072806 Comparator | Jun → Aug 2022 | — | Yonsei University | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-05-23 | Ipsen | New surveys show over 80% of patients with spasticity and cervical dystonia treated with botulinum toxin-A experience debilitating symptom recurrence ipsen.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LetibotulinumtoxinA | “BACKGROUND: Letibotulinum toxin A (LeBA) was approved by the Ministry of Food and Drug Safety (known as the Korea Food & Drug Administration) for cosmetic indications in 2012.” PMID 33721365 ↗ Apr 20213“LetibotulinumtoxinA Attenuates the Psychological Burden of Glabellar Lines and Is Associated With High Subject Satisfaction in Phase 3 Clinical Trials.” PMID 38470985 ↗ Mar 2024 |
| Known as | Botulax | “Botulinum Toxin-A (Botulax - letibotulinumtoxinA)” NCT07668375 ↗ |
| Known as | Botulinum toxin type A | “Botulinum toxin type A(Botulax®)” NCT01791920 ↗ |
| Known as | Botulinum Toxin-A | “Botulinum Toxin-A (Botulax - letibotulinumtoxinA)” NCT07668375 ↗ |
| Known as | LeBA | “BACKGROUND: Letibotulinum toxin A (LeBA) was approved by the Ministry of Food and Drug Safety (known as the Korea Food & Drug Administration) for cosmetic indications in 2012.” PMID 33721365 ↗ Apr 2021 |
| Modality | Protein / enzyme biologic | “Botulinum toxin type A” NCT01791920 ↗ |
| Route | Intramuscular | “20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area.” NCT02677298 ↗ |